Senior Correspondent, London
Ben's Feed
Aug 26, 2014
Aug 25, 2014
Aug 24, 2014
Aug 24, 2014

Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON/ZURICH, Aug 24 (Reuters) – Roche Holding AG
has agreed to buy U.S. biotech company InterMune Inc
for $8.3 billion in cash, marking the latest multibillion-dollar
deal in a consolidating pharmaceutical sector.

The Swiss drugmaker said on Sunday it would pay $74.00 a
share for InterMune, representing a premium of 38 percent to the
closing price on Aug. 22.

Aug 22, 2014
Aug 21, 2014
Aug 21, 2014
Aug 21, 2014

Pfizer back for AstraZeneca? Year-end move seen most likely

LONDON (Reuters) – Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt in May.

But while British takeover rules mean deal talks could be back on the cards as early as Aug. 26, following the ending of the first of a two-stage cooling-off period, many investors and analysts see the year-end as a more likely time for any return.

Aug 21, 2014
Aug 20, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben